Since the addition of the EGFR inhibitor cetuximab to RT demonstrated the improved survival outcomes in LA-HNSCC [8], various anti-EGFR agents have been investigated in patients with LA-HNSCC. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.